(6R,7R)-7-{[(2R)-2-{[(4-Carboxy-1H-imidazol-5-yl)carbonyl]amino}-2-phenylacetyl]amino}-8-oxo-3-{[4-(2-sulfoethyl)-1-pyridiniumyl]methyl}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate(CAS: 84880-03-5)

This compound falls under various regulatory guidelines including OSHA, REACH, FDA, and EPA. It is classified under GHS as a harmful substance due to its potential for skin and eye irritation. REACH requires registration if the substance is manufactured or imported in quantities of 1 tonne or more per year. The FDA may require specific labeling for commercial sale, and the EPA may regulate its disposal to ensure it does not harm the environment.

There are several alternatives to this compound in synthesis, such as imidazolyl derivatives with different substituents, or other 2-sulfoethyl containing compounds. Commonly used alternatives include 4-sulfo-1H-imidazole and 2-sulfoethyl pyridinium derivatives, which can offer similar or different chemical properties depending on the application.

Research trends for this compound are primarily focused on its use in pharmaceuticals and biotechnology due to its unique chemical structure. Market interest is growing in its application for targeted drug delivery and antiviral therapies. Emerging trends include the development of more stable and water-soluble analogs for improved biological activity.

Waste containing this compound should be handled according to local regulations and EPA guidelines. It should be collected in appropriate containers, sealed, and stored in a secure area. For disposal, it is recommended to use professional waste disposal services that can handle hazardous waste. Environmental protection measures include ensuring no leaching or runoff occurs during storage and disposal to prevent contamination of soil and water.